Drug-Shortage List Under Scrutiny After FDA Reversal
A federal agency's unusual flip-flop this month on whether to allow copycat versions of a lucrative weight-loss and diabetes drug may cause regulators to move more cautiously as they weigh how...To view the full article, register now.
Already a subscriber? Click here to view full article